A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia

Iranian Journal of Medical Sciences

Volumn 30, Issue 2, 2005, Pages 59-62

  Farzin, Davood ^a   Hosseini, S H ^a   Shafaat, A ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Famotidine; H2 receptor antagonists; Neuroleptics; Schizophrenia

Indexed keywords

BIPERIDEN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; IRAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

EID: 26044450353     PISSN: 02530716     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. th ed. Baltimore: Williams and Wilkins; 2002. p. 456-500.
2. Ito C. The role of the central histaminergic system on schizophrenia. Drug News & Perspectives 2004; 17: 383-7.
3. Mancama D, Arranz MJ, Munro J, et al. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neuroscience Letters 2002; 333: 207-11.
4. Farzin D, Asghari L, Nowrouzi M. Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists. Pharmacol Biochem Behav 2002; 72: 751-60.
5. Farzin D, Attarzadeh M. Influence of different histamine receptor agonists and antagonists on apomorphine-induced licking behavior in rat. Eur J Pharmacol 2000; 404: 169-74
6. Prell GD, Green JP, Kaufmann CA. Histamine metabolites in CSF of patients with chronic schizophrenia their relationship level of other aminergic transmitters and rating of behavior. Schizophrenia Research 1995; 14: 93-104.
7. Kaminsky R, Moriarty TM, Bodine J, et al. Effect of famotidine on deficit symptoms of schizophrenia. Lancet 1989; 335: 1351-2.
8. Carpenter W, Buchanan R. Schizophrenia (A Review). N Engl J Med 1994; 330: 681-8.
9. Deutsch SI, Rosse RB, Kendrich KA. Famotidine adjunctive pharmacotherapy for schizophrenia. Clinical Neuropharmacology 1993; 16: 518-24.
10. Rifkin A. Pharmacological strategies in treatment of schizophrenia. Psych Clin North America 1993; 19: 351-2.
11. th ed. New York: McGraw-Hill, 1996. p. 901-15.
12. Poyurovsky M, Tal V, Maayan R, et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004; 14: 332-6.
13. Martinez MC. Famotidine in the management of schizophrenia. Annals of Pharmacotherapy 1999; 33: 742-7.
14. Oyewami LK. An open label study of famotidine as a treatment for schizophrenia. J Psychiatry and Neuroscience 1995; 20: 240-5.
15. Rosse RB, Kendrick K, Fay-McCarthy M, et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: Preliminary evidence for treatment efficacy. Clinical Neuropharmacology 1996; 19: 341-8.
16. Dannon PN, Lepkifker E, Iancu I, et al. Famotidine: a supplemental drug for the treatment of schizophrenia. Eur Psychiatry 1997; 12: 263-4.
17. 2 blocker: Augmentation treatment of schizophrenia. Andeesheh va Raftar 2000; 4: 10-7.
18. Whiteford HA, Stedman TJ, McGrath J, et al. An open label study of famotidine as a treatment for schizophrenia. J Psychiatry and Neuroscience 1995; 20: 239-40.